ALVO
Alvotech NASDAQ Listed Jun 16, 2022$5.87
+9.93%
vs $5.34
Mkt Cap $2.0B
52w Low $2.94
46.4% of range
52w High $9.25
50d MA $4.19
200d MA $4.15
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-5.1x
ROE
—
P/FCF
-14.3x
RSI (14)
75.00
ATR (14)
$0.26
Beta
0.25
50d MA
$4.19
200d MA
$4.15
Avg Volume
1.1M
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
Saemundargata 15-19 · Luxembourg, N4 102 · IS
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19, 2026 | AMC | -0.05 | -0.11 | -109.1% | 3.99 | -2.5% | +7.0% | +3.7% | +18.5% | -3.8% | -2.8% | — |
| May 6, 2026 | AMC | -0.07 | -0.09 | -28.6% | 3.57 | -7.3% | -10.4% | +1.9% | +10.1% | -1.1% | +3.4% | — |
| Mar 18, 2026 | AMC | -0.01 | -0.37 | -6335.7% | 3.80 | -3.7% | -5.8% | -1.4% | -5.7% | -6.0% | +0.3% | — |
| Nov 12, 2025 | AMC | -0.03 | -0.02 | +24.8% | 5.60 | -7.0% | -1.4% | -0.5% | -6.4% | -0.6% | +2.3% | — |
| Aug 13, 2025 | AMC | -0.05 | 0.14 | +403.3% | 8.96 | -1.2% | -5.4% | -5.3% | +12.1% | -3.4% | -5.4% | — |
| May 7, 2025 | AMC | -0.08 | 0.35 | +537.5% | 7.94 | +17.1% | +18.1% | +3.2% | +5.9% | +3.0% | -0.6% | — |
| Mar 26, 2025 | AMC | -0.03 | -0.14 | -420.5% | 11.55 | -0.7% | -10.3% | -7.8% | +1.3% | -0.3% | -4.7% | — |
| Nov 13, 2024 | AMC | -0.06 | -0.03 | +52.4% | 11.93 | +5.4% | +1.2% | -2.8% | +3.2% | +3.3% | -0.6% | — |
| Aug 15, 2024 | AMC | -0.28 | 0.28 | +200.0% | 11.93 | +6.0% | +8.7% | +0.2% | -2.6% | -2.0% | -3.5% | — |
| May 21, 2024 | AMC | -0.08 | -0.89 | -1012.5% | 13.94 | +1.5% | +0.4% | -3.0% | +4.5% | -1.4% | -2.8% | — |
| Mar 20, 2024 | AMC | 0.04 | -1.22 | -3150.0% | 15.23 | -1.6% | -1.1% | -0.8% | -11.2% | -5.8% | +1.4% | — |
| Nov 29, 2023 | AMC | -0.07 | -0.82 | -1071.4% | 9.40 | +4.0% | +1.1% | -0.5% | +0.4% | -1.5% | +1.6% | — |
| Nov 28, 2023 | AMC | -0.29 | -0.82 | -182.8% | 9.80 | +1.0% | -4.1% | +1.1% | -0.5% | +0.4% | -1.5% | — |
| Aug 30, 2023 | AMC | -0.14 | -0.43 | -207.1% | 9.73 | +0.2% | +1.7% | +0.4% | -0.7% | -2.3% | -2.0% | — |
| May 19, 2023 | AMC | — | -0.33 | — | 8.33 | +1.3% | +2.2% | -4.2% | -4.7% | -2.7% | +6.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 16 | Barclays | Upgrade | Underweight → Overweight | $8 | $5.02 | $5.40 | +7.6% | +1.6% | +4.7% | +9.9% | — | — |
| Aug 24 | BofA Securities | Initiates | Buy | $7 | $4.43 | $4.79 | +8.1% | +18.5% | -3.8% | -2.8% | -0.6% | +1.4% |
| Aug 14 | Evercore ISI | Initiates | Outperform | — | $4.09 | $4.15 | +1.5% | -0.7% | -4.4% | +1.8% | +1.0% | +7.0% |
| Mar 24 | UBS | Maintains | Buy → Buy | — | $3.33 | $3.28 | -1.5% | -6.0% | +0.3% | +3.2% | -4.0% | +5.8% |
| Mar 24 | Barclays | Maintains | Underweight → Underweight | — | $3.33 | $3.28 | -1.5% | -6.0% | +0.3% | +3.2% | -4.0% | +5.8% |
| Nov 18 | UBS | Maintains | Buy → Buy | — | $5.14 | $5.11 | -0.6% | -0.6% | +2.3% | -3.3% | +1.6% | +6.4% |
| Nov 4 | Deutsche Bank | Downgrade | Buy → Hold | — | $5.03 | $5.09 | +1.2% | -4.0% | +1.0% | +3.7% | +12.8% | -4.0% |
| Oct 14 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $7.97 | $8.30 | +4.1% | +6.6% | +5.6% | -2.6% | -0.3% | -1.5% |
| Sep 23 | Deutsche Bank | Upgrade | Hold → Buy | — | $8.01 | $8.35 | +4.2% | +8.6% | -1.4% | -5.4% | +2.7% | +0.7% |
| Jul 18 | UBS | Maintains | Buy → Buy | — | $8.73 | $8.75 | +0.2% | -1.1% | +0.1% | +0.5% | +5.5% | +0.0% |
| Jul 25 | Barclays | Maintains | Overweight → Overweight | — | $11.60 | $11.60 | +0.0% | -2.7% | +2.7% | +1.9% | -0.1% | -0.8% |
| May 24 | Barclays | Maintains | Overweight → Overweight | — | $13.58 | $13.70 | +0.9% | +4.5% | -1.4% | -2.8% | +1.2% | +0.8% |
| Mar 22 | Barclays | Maintains | Overweight → Overweight | — | $15.07 | $15.00 | -0.5% | -0.8% | -11.2% | -5.8% | +1.4% | -3.6% |
| Jan 29 | Barclays | Upgrade | Equal Weight → Overweight | — | $14.65 | $15.00 | +2.4% | +4.1% | -0.8% | +4.1% | +1.3% | -1.6% |
| Oct 20 | Citigroup | Upgrade | Sell → Neutral | — | $8.85 | $8.86 | +0.1% | -1.9% | +1.4% | -0.5% | -0.7% | -1.7% |
| Mar 7 | Deutsche Bank | Maintains | Hold → Hold | — | $14.01 | $14.10 | +0.6% | -0.1% | -2.4% | -5.9% | +2.9% | +1.1% |
| Sep 6 | Citigroup | Downgrade | Buy → Sell | — | $7.56 | $7.25 | -4.1% | -4.8% | +6.5% | +3.3% | +1.0% | -2.5% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Millennium Management Llc | 4,263,644 | $16M | Added | Jun 2026 |
| 2 | Bracebridge Capital, Llc | 4,038,637 | $15M | New | Jun 2026 |
| 3 | Vanguard Capital Management Llc | 3,689,612 | $14M | Added | Jun 2026 |
| 4 | Citadel Advisors Llc | 3,456,004 | $13M | New | Jun 2026 |
| 5 | Farallon Capital Management, L.l.c. | 2,859,675 | $11M | Added | Jun 2026 |
| 6 | Blackrock, Inc. | 1,327,282 | $5M | New | Jun 2026 |
| 7 | Littlejohn & Co Llc | 1,318,534 | $5M | — | Jun 2026 |
| 8 | Morgan Stanley | 510,448 | $3M | Added | Dec 2025 |
| 9 | Jpmorgan Chase & Co | 504,201 | $2M | Added | Mar 2026 |
| 10 | Ubs Group Ag | 322,157 | $1M | Added | Mar 2026 |
| 11 | Vanguard Asset Management, Ltd | 151,935 | $527K | New | Mar 2026 |
| 12 | Jane Street Group, Llc | 92,314 | $474K | New | Dec 2025 |
| 13 | Ulland Investment Advisors, Llc | 109,500 | $404K | Added | Jun 2026 |
| 14 | Oaktree Capital Management Lp | 97,982 | $362K | — | Jun 2026 |
| 15 | Oaktree Fund Advisors, Llc | 76,023 | $281K | Reduced | Jun 2026 |
| 16 | Invesco Ltd. | 78,447 | $269K | Added | Mar 2026 |
| 17 | Savant Capital, Llc | 77,818 | $267K | New | Mar 2026 |
| 18 | China Universal Asset Management Co., Ltd. | 51,006 | $262K | Reduced | Dec 2025 |
| 19 | Quadrature Capital Ltd | 66,599 | $246K | Added | Jun 2026 |
| 20 | Richmond Brothers, Inc. | 44,830 | $165K | Added | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 8
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND | 1,562,460 | $8M | Jan 2026 |
| 2 | VANGUARD EMERGING MARKETS STOCK INDEX FUND | 1,489,165 | $8M | Jan 2026 |
| 3 | VANGUARD FTSE ALL-WORLD EX-US INDEX FUND | 257,257 | $1M | Jan 2026 |
| 4 | iShares Genomics Immunology and Healthcare ETF | 163,916 | $880K | Jan 2026 |
| 5 | VANGUARD TOTAL WORLD STOCK INDEX FUND | 76,122 | $398K | Jan 2026 |
| 6 | Invesco RAFI US 1500 Small-Mid ETF | 57,082 | $307K | Jan 2026 |
| 7 | Invesco Nasdaq Biotechnology ETF | 17,492 | $70K | Feb 2026 |
| 8 | Knights of Columbus U.S. ALL CAP INDEX FUND | 601 | $3K | Jan 2026 |
Valuation
Market Cap
$1.99B
Enterprise Value
$2.73B
P/E (TTM)
—
Forward P/E
185.17x
PEG Ratio
-0.46x
P/B
—
P/S
4.04x
P/FCF
-14.29x
EV/EBITDA
—
Shares Out
279.2M
Financials (TTM)
Revenue
$492.0M
Net Income
-$179.6M
EBITDA
-$1.4M
Free Cash Flow
-$114.7M
Op Cash Flow
-$50.2M
EPS Basic
$0.10
EPS Diluted
$-0.63
EPS Forward
$0.03
Gross Margin
60.5%
Op Margin
9.6%
Net Margin
-36.5%
Balance Sheet
Total Assets
$1.49B
Total Liab.
$1.77B
Total Equity
-$284.5M
Cash
$172.4M
LT Debt
$1.26B
Book Value/Sh
$-1.02
Debt/Equity
-5.09x
Current Ratio
1.89
Quick Ratio
1.16
Returns & Growth
ROE
—
ROA
—
ROIC
1.3%
Rev Growth YoY
+19.7%
EPS Growth YoY
+111.5%
Price Returns
2W
+9.1%
1M
+47.1%
3M
+60.8%
6M
+64.0%
12M
-25.5%
Technicals
52W High
$9.25
52W Low
$2.94
50d MA
$4.19
200d MA
$4.15
RSI (14)
75.00
ATR (14)
$0.26
Beta
0.25
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$8.60
High
$10.00
Low
$5.00
Median
$10.00
Data updated apr 24, 2026 5:36pm
· Source: financialmodelingprep.com